CLINICAL ACTIONS:

Vulvovaginal candidiasis (VVC) presents with symptoms of itching, redness and discharge. Recurrent VVC (RVVC) is diagnosed when women have ≥4 episodes of VVC within 12 months.

• Focus on the following when obtaining the history
  • Location | Duration | Relation to menses | Response to prior treatment and self-treatment | Sexual partners | Contraception
  • Note: Self-diagnosis and telephone diagnosis are unreliable
• Physical exam includes examination of vulva and vaginal vault
  • Signs of inflammation | Ulcers | Excoriation
• Diagnosis
  • Blastospores or pseudohyphae on saline or 10% KOH microscopy or
  • Positive culture in the presence of symptoms suggestive of candidiasis and negative microscopy

Note: Sensitivity of microscopy is only 50% to 70% and many cases will go undetected | False negative work-up more likely if patient has self-treated with OTC medications | Newer FDA approved commercial tests have higher sensitivities and “may prove to be useful”

Classification

Classify as uncomplicated or complicated

• Uncomplicated
  • Sporadic or infrequent
  • Candida albicans infection (suspected or proven)
  • Non-immunocompromised
  • Mild/ moderate symptoms and findings
• Complicated
  • Recurrent: ≥4 infections in 12 months
  • Severe symptoms and findings
  • Non-Albicans Candida (NAC)
  • Immunocompromised, including
    • Diabetes | Immunosuppression meds | HIV

SYNOPSIS:

VVC is a common clinical condition with most infections due to C. albicans. Uncomplicated infections respond promptly to 1-,3- and 7- day treatment options (see below).  Complicated/recurrent VVC may require longer duration of treatment and higher doses of medication.  NAC subtypes may be resistant to typical treatment.

KEY POINTS:

• Candida albicans is the most common cause of VVC
• NAC
  • Accounts for an increasing number of cases
  • NAC species include
    • glabrata | C. tropicalis | C. krusei | C. parapsilosis | C. guilliermondii
  • Correct identification is important as NACs have resistance/decreased susceptibilities to commonly used treatment

Treatment

Uncomplicated

• One-day therapy
  • Butoconazole 2% sustained-release cream intravaginally 5 g or
  • Fluconazole 150 mg po (Note – only oral agent) or
  • Miconazole 1,200 mg vaginal suppository or
  • Tioconazole 6.5% ointment 5 gram intravaginally
• 3-day therapy
  • Clotrimazole 2% cream 5 g daily intravaginally or
  • Miconazole 200 mg vaginal suppository daily or
  • Miconazole 4% cream 5 g intravaginally daily or
  • Terconazole 0.8% cream 5 gm intravaginally daily  or
  • Terconazole 80 mg vaginal suppository daily
• 7-day therapy
  • Clotrimazole 1% cream 5 g intravaginally daily or
  • Miconazole 2% cream 5 g intravaginally daily or
  • Miconazole 100 mg vaginal suppository
  • Terconazole 0.4% cream 5g intravaginally daily

Complicated 

• Fluconazole “is an effective and convenient treatment”

Recurrence (Candida albicans)

• Intensive therapy for 7–14 days
• Followed by prolonged treatment with fluconazole (first line)
  • Fluconazole 150 mg weekly for 6 months
• Acceptable alternative prolonged therapy (second line) if patient does not want or cannot tolerate fluconazole
  • Clotrimazole 500 mg weekly or
  • Clotrimazole 200 mg twice a week

Severe Infection (erosions, fissures, edema)

• Acute infection
  • Topical intravaginal azoles for 10 to 14 days or
  • Oral fluconazole every 3 days (day 1, 4 and 7)

If NAC confirmed

• Approximately 50% of patients may respond to topical imidazole treatment
• If unresponsive to topical imidazole treatment use
  • Boric acid 600 mg vaginal capsules daily x 14 days (minimum)
• If unresponsive patient, should be referred to a subspecialist

Pregnancy

• Only topical azole therapies for 7 days are recommended (CDC)

Note: The CDC states “Epidemiologic studies indicate a single 150-mg dose of fluconazole might be associated with spontaneous abortion and congenital anomalies; therefore, it should not be used”

Other treatments

• Data on the efficacy of the following are currently inconclusive
  • Probiotics | Yogurt | Garlic | Tea tree oil | Low carb diet | Depot medroxyprogesterone | Douching

Learn More – Primary Sources:

ACOG Practice Bulletin 215: Vaginitis in Nonpregnant Patients

An Update on the Roles of Non-albicans Candida Species in Vulvovaginitis

Recurrent Vulvovaginitis

BMJ Clinical Evidence: Candidiasis (vulvovaginal)

CDC STI Treatment Guidelines 2021: Vulvovaginal Candidiasis

BMJ: Recurrent vulvovaginal candidiasis

Related ObG Topics:

Diagnosing Vaginitis – Why the Office Visit Still Matters

Cochrane Review: Oral or Intra-Vaginal Anti-Fungal Treatment for Candidiasis?

What is ‘Mixed’ Vaginitis? How and When to Treat

FDA Reviews Fluconazole in Pregnancy

Bacterial Vaginosis – CDC Diagnosis and Treatment Recommendations

Trichomoniasis: CDC Diagnosis and Treatment Guidelines